The association of human papillomavirus vaccine with premature ovarian failure: A systematic review

Document Type : Review Article


1 PhD Candidate of Reproductive Health, Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Instructor, Department of Midwifery, Ardabil Branch, Islamic Azad University, Ardabil, Iran.

2 PhD Candidate of Reproductive Health, Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Associate Professor, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Introduction: The most important factor initiating cervical cancer is human papilloma virus (HPV) infection; although the HPV vaccine can significantly prevent the infection in women, there is contradictory findings about its side effects such as premature ovarian failure (POF). The present systematic review was conducted with aim to determine the association between this vaccine and POF.
Methods: This study was conducted by search in the reliable databases of PubMed, Web of Science, Google Scholar, Embase, and Scopus by two researchers independently based on the PICO guidelines and the use of Mesh terms including Papillomavirus vaccine, Human Papillomavirus Recombinant Vaccine Quadrivalent, Primary Ovarian Insufficiency and Premature Ovarian Failure. Newcastle - Ottawa checklist was used to evaluate the quality of articles.
Results: After review and evaluation of the quality of 128 primary articles, finally 7 articles were included in the systematic review. According to the results of population-based studies, there was no significant relationship between the HPV vaccine and POF; but there are case series which support the association between the HPV vaccine and POF. They declared that the cause of this complication was the induction of autoimmune response by the vaccine and the side-effects of the adjuvant used in it.
Conclusion: Considering that the HPV vaccine is currently the most effective approach in preventing cervical cancer, it seems more reasonable to use preventive benefits of this vaccine. Further studies emphasizing the possible side effects of the vaccine can minimize the challenges associated with this vaccine in the future.


  1. Ruddies F, Gizaw M, Teka B, Thies S, Wienke A, Kaufmann AM, et al. Cervical cancer screening in rural Ethiopia: a cross-sectional knowledge, attitude and practice study. BMC cancer 2020; 20(1):1-0.
  2. Nejati A, Mirteimouri M, Nikdoust S, Nikdoust M, Alizadeh F. Human Papillomavirus (HPV) test and Pap Smear in Screening for Cervical Cancer: A systematic review on systematic review study. Iran J Obstet Gynecol Infertil 2020; 23(7):88-96.
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2021; 71(3):209-49.
  4. Woo YL, Gravitt P, Khor SK, Ng CW, Saville M. Accelerating action on cervical screening in lower-and middle-income countries (LMICs) post COVID-19 era. Preventive medicine 2021; 144:106294.
  5. Kasamatsu E, Rodríguez Riveros MI, Soilan AM, Ortega M, Mongelós P, Páez M, et al. Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay. PloS one 2019; 14(6):e0218016.
  6. Camara HB, Anyanwu M, Wright E, Kimmitt PT. Human papilloma virus genotype distribution and risk factor analysis amongst reproductive-age women in urban Gambia. Journal of Medical Microbiology 2018; 67(11):1645-54.
  7. Liu B, Taioli E. Associations between human papillomavirus and history of cancer among US adults in the National Health and Nutrition Examination Survey (2003–2010). British journal of cancer 2014; 111(7):1448-53.
  8. Östensson E, Belkić K, Ramqvist T, Mints M, Andersson S. Self‑sampling for high‑risk human papillomavirus as a follow‑up alternative after treatment of high‑grade cervical intraepithelial neoplasia. Oncology Letters 2021; 21(4):1.
  9. Gross G. Genitoanal human papillomavirus infection and associated neoplasias. InHuman Papillomavirus 2014; 45:98-122.
  10. Taebi M, Riazi H, Keshavarz Z, Afrakhteh M. Knowledge and attitude toward human papillomavirus and HPV vaccination in Iranian population: a systematic review. Asian Pacific Journal of Cancer Prevention: APJCP 2019; 20(7):1945-9.
  11. Pho AT, Bakken S, Lunn MR, Lubensky ME, Flentje A, Dastur Z, et al. Online health information seeking, health literacy, and human papillomavirus vaccination among transgender and gender-diverse people. Journal of the American Medical Informatics Association 2022; 29(2):285-95.
  12. Barchitta M, Maugeri A, La Mastra C, La Rosa MC, Favara G, Magnano San Lio R, et al. Dietary antioxidant intake and human papillomavirus infection: evidence from a cross-sectional study in Italy. Nutrients. 2020 May;12(5):1384.
  13. Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani S, et al. Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru. International Journal of Gynecologic Cancer 2011; 21(9):1654-63.
  14. Becker ER, Shegog R, Savas LS, Frost EL, Coan SP, Healy CM, et al. Parents’ Experience With a Mobile Health Intervention to Influence Human Papillomavirus Vaccination Decision Making: Mixed Methods Study. JMIR Pediatrics and Parenting 2022; 5(1):e30340.
  15. Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. American Journal of Reproductive Immunology 2013; 70(4):309-16.
  16. Phillips A, Hickie M, Totterdell J, Brotherton J, Dey A, Hill R, et al. Adverse events following HPV vaccination: 11 years of surveillance in Australia. Vaccine 2020; 38(38):6038-46.
  17. Si M, Su X, Jiang Y, Qiao Y, Liu Y. Interventions to improve human papillomavirus vaccination among Chinese female college students: study protocol for a randomized controlled trial. BMC Public Health 2019; 19(1):1-10.
  18. George C, Roberts R, Brennen D, Deveaux L, Read SE. Knowledge and awareness of Human Papillomavirus (HPV) and HPV vaccines among Caribbean youth: the case of the Bahamas. Human Vaccines & Immunotherapeutics 2020; 16(3):573-80.
  19. World Health Organization. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. World Health Organization; 2019.
  20. Little DT, Ward HR. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice. Journal of investigative medicine high impact case reports 2014; 2(4):2324709614556129.
  21. Naleway AL, Mittendorf KF, Irving SA, Henninger ML, Crane B, Smith N, et al. Primary ovarian insufficiency and adolescent vaccination. Pediatrics 2018; 142(3).
  22. Tatang C, Arredondo Bisonó T, Bergamasco A, Salvo F, Costa Clemens SA, Moride Y. Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System. Drugs-Real World Outcomes 2022; 9(1):79-90.
  23. Gong L, Ji HH, Tang XW, Pan LY, Chen X, Jia YT. Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: Data mining of Vaccine Adverse Event Reporting System. Scientific reports 2020; 10(1):1-8.
  24. Little DT, Ward HR. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. Case Reports 2012; 2012:bcr2012006879.
  25. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC medical research methodology 2014; 14(1):1-5.
  26. Hviid A, Thiesson EM. Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort. JAMA network open 2021; 4(8):e2120391-.
  27. Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015. Vaccine 2018; 36(13):1781-8.
  28. Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Human vaccines & immunotherapeutics 2016; 12(6):1406-17.
  29. Sharif K, Watad A, Bridgewood C, Kanduc D, Amital H, Shoenfeld Y. Insights into the autoimmune aspect of premature ovarian insufficiency. Best Practice & Research Clinical Endocrinology & Metabolism 2019; 33(6):101323.
  30. Shareghi-Oskoue O, Aghebati-Maleki L, Yousefi M. Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure. Stem Cell Research & Therapy 2021; 12(1):1-3.
  31. DeLong G. Lowered female fertility associated with human papilloma virus vaccines. International Journal of Vaccine Theory, Practice, and Research 2021; 2(1):125-48.
  32. Baker B, Eça Guimarães L, Tomljenovic L, Agmon-Levin N, Shoenfeld Y. The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opinion on Drug Safety 2015; 14(9):1387-94.
  33. Christianson MS, Wodi P, Talaat K, Halsey N. Primary ovarian insufficiency and human papilloma virus vaccines: a review of the current evidence. American journal of obstetrics and gynecology 2020; 222(3):239-44.
  34. Little DT, Ward HR. Ongoing inadequacy of quadrivalent HPV vaccine safety studies. BMJ Evidence-Based Medicine 2020; 25(2):44-5.
  35. Markowitz LE, Gee J, Chesson H, Stokley S. Ten years of human papillomavirus vaccination in the United States. Academic pediatrics 2018; 18(2):S3-10.
  36. McGlacken-Byrne SM, Conway GS. Premature ovarian insufficiency. Best Pract Res Clin Obstet Gynaecol 2022; 81:98-110.